Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**DC-006** is an investigational, personalized autologous dendritic-cell cancer vaccine developed for recurrent platinum-sensitive epithelial ovarian cancer. Patient-derived dendritic cells are transfected with mRNA from amplified ovarian cancer stem cells together with mRNAs encoding human telomerase reverse transcriptase and survivin. The vaccine is intended to present these tumor-associated antigens to the immune system and induce cytotoxic T-cell responses against ovarian cancer cells expressing hTERT, survivin, and ovarian cancer stem-cell antigens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DC-006.